fludarabine + rituximab

Fludarabine + rituximab is a combination regimen used primarily in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (B-NHL). Fludarabine is a purine analog that inhibits DNA synthesis by interfering with DNA polymerase and ribonucleotide reductase activity. Rituximab is a monoclonal antibody targeting CD20 on B-lymphocytes; it induces cell lysis through complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct induction of apoptosis. The combination exploits the synergistic effects of both agents to deplete malignant B cells more effectively than either agent alone[1][5][8]. This regimen is often used in relapsed or refractory cases and may be administered orally or intravenously.

Other names

fludarabine phosphateRITUXANMABTHERA